Billiontoone (NASDAQ:BLLN) CEO Oguzhan Atay Sells 5,150 Shares of Stock

Posted by Stacy Sanders on Oct 17th, 2026

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CEO Oguzhan Atay sold 5,150 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $100.23, for a total value of $516,184.50. Following the transaction, the chief executive officer directly owned 3,183 shares of the company’s stock, valued at $319,032.09. The trade was a 61.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $261,366.00.
On Wednesday, October 14th, Oguzhan Atay sold 3,183 shares of Billiontoone stock. The stock was sold at an average price of $98.34, for a total value of $313,016.22.
On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $97.61, for a total value of $260,325.87.
On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The shares were sold at an average price of $93.79, for a total value of $1,563,197.93.
On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total value of $321,626.24.
On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total value of $1,005,293.12.
On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $522,536.00.
On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The stock was sold at an average price of $100.32, for a total value of $2,507,899.68.
On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total transaction of $1,717,125.00.
On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total transaction of $4,450,875.00.

Billiontoone Trading Down 4.5%

Billiontoone stock traded down $4.61 during mid-day trading on Friday, reaching $98.12. 605,635 shares of the company traded hands, compared to its average volume of 654,157. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The firm has a market capitalization of $4.63 billion and a price-to-earnings ratio of 140.17. The firm’s 50 day moving average price is $100.99 and its 200 day moving average price is $101.58.

Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. The firm had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, analysts anticipate that Billiontoone, Inc. will post 0.80 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BLLN. Wasatch Advisors LP boosted its stake in Billiontoone by 40.2% during the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after acquiring an additional 148,446 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of Billiontoone by 26.8% during the first quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock valued at $18,911,000 after purchasing an additional 50,613 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Billiontoone by 11.9% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after purchasing an additional 14,072 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Billiontoone by 26.1% during the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock valued at $7,248,000 after purchasing an additional 19,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Billiontoone in the 1st quarter worth approximately $4,046,000.

Wall Street Analyst Weigh In

Several analysts have commented on BLLN shares. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Guggenheim upped their target price on Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a research note on Friday, October 2nd. Finally, JPMorgan Chase & Co. dropped their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $126.25.

Get Our Latest Analysis on Billiontoone

About Billiontoone

(Get Free Report)

BillionToOne, Inc (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.